Skip to content

Novel treatment of Acanthamoeba Keratitis

A Pilot project for assessment of safety and efficacy of miltefossine in the treatment of Acanthamoeba Keratitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020875
Enrollment
5
Registered
2019-08-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H160- Corneal ulcer

Interventions

Intervention1: Topical miltefossine: Patients of Acanthamoeba keratitis Route of administration is topical every hourly for 1 week followed by every 2 hourly. Control Intervention1: Not Applicable:

Sponsors

LV Prasad Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age equal to or more than 18 years. 2) Male or female 3) Stromal infiltrate size between 4) Corneal scraping positive for Acanthamoeba cysts in direct smear examination by any one or more of the methods used.

Exclusion criteria

Exclusion criteria: 1) The corneal scrapings are negative for Acanthamoeba. 2)The patient has a history of allergy to Miltefosine 3) The cornea or sclera has been perforated or perforation is impending. 4)The unaffected eye is legally blind. . 5)The patient is known to be HIV positive or diabetic. 6)The initial culture shows significant growth of bacteria ( >10 colonies) or fungus. 7)Both eyes are infected.

Design outcomes

Primary

MeasureTime frame
Size of the infiltrate and inflammatory signsTimepoint: Size of the infiltrate and inflammatory signs. complete Resolution of infection or resolving infection

Secondary

MeasureTime frame
Number of patients went to therapeutic TreatmentTimepoint: 1 month

Countries

India

Contacts

Public ContactDrBhupesh Bagga

LV Prasad Eye Institute

bhupesh@lvpei.org04030612615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026